Loading...
•
Mar 31, 2025
Bicycle Q1 2025 Earnings Report
Reported Q1 2025 financial results and recent business progress
Key Takeaways
Bicycle Therapeutics reported a net loss of $60.8 million for Q1 2025, compared to a net loss of $26.6 million in the prior year period, driven by increased R&D and G&A expenses. Collaboration revenue decreased. The company ended the quarter with $793.0 million in cash and cash equivalents, extending its financial runway into the second half of 2027. Progress was made on the pipeline, including initiating a Phase 1/2 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer.
Net loss widened to $60.8 million in Q1 2025 from $26.6 million in Q1 2024.
Collaboration revenue was $10.0 million, down from $19.5 million in the prior year period.
Cash and cash equivalents stood at $793.0 million as of March 31, 2025, providing runway into 2H 2027.
Advanced pipeline with initiation of Phase 1/2 Duravelo-3 trial and progress in Duravelo-2 trial.
Forward Guidance
The company expects its cash runway to extend into the second half of 2027. Key clinical milestones anticipated in the second half of 2025 include dose selection for the Duravelo-2 trial and initial human imaging data for an EphA2 BRC molecule. Company-sponsored BRC clinical trials are planned for 2026.
Positive Outlook
- Expected financial runway into 2H 2027.
- On track for dose selection in Phase 2/3 Duravelo-2 trial in 2H 2025.
- Initial EphA2 human imaging data expected in 2H 2025.
- Company-sponsored BRC clinical trials planned for 2026.
- Duravelo-3 trial for NECTIN4-amplified breast cancer is actively recruiting.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...